Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. (Q46398147)
Jump to navigation
Jump to search
scientific article published on 31 August 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. |
scientific article published on 31 August 2008 |
Statements
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels (English)
Donna L Forrest
Shannon Trainor
Michael J Barnett
Donna E Hogge
Thomas J Nevill
John D Shepherd
Stephen H Nantel
Cynthia L Toze
Heather J Sutherland
Kevin W Song
Julye C Lavoie
Maryse M Power
Yasser Abou-Mourad
Clayton A Smith
31 August 2008